Tranexamic Acid

• Heavy Menstrual Bleeding
• Hemophilia Dental Procedures
• Trauma Hemorrhage
• Perioperative Bleeding

Tranexamic acid (brand names Lysteda and Cyklokapron) is an antifibrinolytic medication that reduces bleeding by stabilizing blood clots. It is FDA-approved to treat heavy menstrual bleeding in women, to prevent dental procedure bleeding in patients with hemophilia, and to reduce perioperative blood loss in cardiac surgery. Off-label, it is widely used in trauma resuscitation, postpartum hemorrhage, recurrent epistaxis, hereditary angioedema prophylaxis, and topical formulations for melasma. For internal medicine practice, the most common scenario is the woman with menorrhagia who wants to reduce menstrual blood loss without using hormonal therapy, particularly when hormonal options are contraindicated, ineffective, or simply unwanted.

Mechanism of Action

Normal hemostasis depends on a balance between clot formation and clot dissolution. After a clot forms, the protein plasminogen, embedded in the fibrin matrix, is converted to active plasmin by tissue plasminogen activator. Plasmin then digests fibrin, breaking the clot down and allowing tissue to heal without leaving permanent occlusions. In conditions like heavy menstrual bleeding, this fibrinolytic process is excessive in the endometrium, allowing greater blood loss than normal.

Tranexamic acid is a lysine analog that competitively binds the lysine-binding sites on plasminogen, blocking its attachment to fibrin and preventing conversion to active plasmin. The clot is preserved longer, fibrin breakdown slows, and bleeding decreases. Tranexamic acid is approximately ten times more potent than its predecessor aminocaproic acid for the same indication. The drug works only on plasminogen activation; it does not directly form clots, increase platelet count, or affect coagulation factor levels, so it is generally considered safer than truly procoagulant strategies. However, by preserving any clots that form - including unwanted thrombi in the venous or arterial circulation - tranexamic acid does carry a real, if modest, increase in thrombosis risk that becomes clinically significant in patients with thrombophilia, prior venous thromboembolism, or concurrent hormonal contraception. The full mechanism and FDA label data are available through DailyMed, and the American Society of Hematology summarizes use in bleeding disorders at hematology.org. Tranexamic acid is renally eliminated largely unchanged, which makes serum creatinine the most important guide to dose adjustment.

Clinical Use

For heavy menstrual bleeding, tranexamic acid reduces menstrual blood loss by 30 to 60 percent in randomized trials, making it one of the most effective non-hormonal options. It is preferred for women who do not want hormonal contraception, who have contraindications to estrogen, who are perimenopausal and do not need contraception, or who specifically want a medication used only during their period rather than continuously. The American College of Obstetricians and Gynecologists endorses tranexamic acid as a first-line option for heavy menstrual bleeding alongside levonorgestrel intrauterine devices, NSAIDs, and combined hormonal contraceptives. Compared with NSAIDs, tranexamic acid produces greater blood-loss reduction; compared with hormonal IUDs, it is less effective overall but available immediately without procedures. For patients whose menstrual losses are significant enough to produce iron-deficiency anemia, reducing flow with tranexamic acid often allows iron stores to recover over months.

In trauma, the CRASH-2 trial established that intravenous tranexamic acid given within three hours of significant injury reduces all-cause mortality. The CRASH-3 trial showed similar benefit in mild-to-moderate traumatic brain injury when given early. In postpartum hemorrhage, the WOMAN trial demonstrated reduced death from bleeding when given within three hours. These trauma and obstetric uses are typically administered by emergency or hospital teams, not in outpatient internal medicine. Patient selection for outpatient menstrual use favors women without thrombophilia, prior venous thromboembolism, recent stroke, or active vascular disease. Co-prescription with estrogen-containing contraceptives slightly increases thrombotic risk; this combination is generally avoided when possible. For patients on warfarin, apixaban, rivaroxaban, or edoxaban, the indication for tranexamic acid is reviewed carefully because the underlying reason for anticoagulation is itself a relative contraindication. For lifestyle context on iron-deficiency recovery, see our article on understanding blood work and lab panels.

How to Take It

For heavy menstrual bleeding in adults, the standard oral dose is 1300 mg (two 650 mg tablets) three times daily for up to five days during each menstrual cycle, with a daily maximum of 3900 mg. Treatment begins on the first day of the period and is continued only on heavy bleeding days. Tablets are taken with food and a full glass of water and should not be crushed or chewed because the formulation is designed to release at a controlled rate. Treatment is not continuous between cycles - the drug is used episodically, only during menses.

If a dose is missed and remembered within several hours, take it; if it is close to the next dose, skip and resume the schedule. Most women notice reduced flow during the first cycle of use; full benefit is usually established by the second or third cycle. If bleeding is unchanged after two to three cycles, the medication is unlikely to be effective and an alternative or further evaluation is appropriate. Store tablets at room temperature in their original container. The first cycle of use occasionally brings mild headache, sinus congestion, abdominal cramping, or back pain; these typically improve with subsequent cycles. Patients should not exceed five days of use per cycle without a clinician discussion. Patients who are on combined hormonal contraceptives should discuss with their clinician whether to continue them during the days they are also taking tranexamic acid; some clinicians prefer to overlap, while others recommend a brief interruption based on individualized risk.

Monitoring and Follow-Up

A pre-treatment evaluation establishes that bleeding is in fact menorrhagic - typically defined as more than 80 mL per cycle or as flow that interferes with daily life - and excludes structural causes such as fibroids, polyps, hyperplasia, or malignancy. A pelvic exam, complete blood count to assess for anemia, ferritin, TSH, and pregnancy test are standard. Pelvic ultrasound is obtained when structural pathology is suspected. A personal and family history of thrombosis, miscarriage, stroke before age 50, or known thrombophilia is reviewed; positive findings warrant a hematology consultation before starting.

Follow-up after two to three cycles assesses response, tolerability, and improvement in associated iron-deficiency anemia. A repeat hemoglobin and ferritin three to six months after starting often shows substantial recovery as menstrual losses fall. No routine pharmacologic monitoring is required - tranexamic acid does not require blood-level checks or coagulation panels. However, any new symptoms suggesting thrombosis - calf swelling or pain, sudden shortness of breath, chest pain, headache with neurologic deficit, vision changes - require immediate discontinuation and emergency evaluation. Annual reassessment confirms ongoing indication; many women transition to a hormonal IUD or definitive procedural management over time. For patients with renal impairment, periodic creatinine measurement guides ongoing dose appropriateness, and patients with declining function should have the dose lowered before symptoms develop. Vision should be assessed at baseline and at annual visits because color-vision changes can develop insidiously.

Special Populations

In renal impairment, the dose is reduced based on serum creatinine: creatinine 1.4 to 2.8 mg/dL receives 1300 mg twice daily; 2.9 to 5.7 mg/dL receives 1300 mg once daily; greater than 5.7 mg/dL receives 650 mg once daily. No specific hepatic dose adjustment exists. Tranexamic acid is contraindicated in active thromboembolic disease, history of arterial or venous thrombosis, intrinsic risk of thrombosis such as antiphospholipid syndrome, subarachnoid hemorrhage (because of cerebral edema and infarction risk), and color vision deficits.

Pregnancy data are limited; the drug is used in obstetric hemorrhage but is not first-line for routine antenatal heavy bleeding. Lactation data show low milk concentrations and breastfeeding is generally considered acceptable. Pediatric use is established for dental procedures in hemophilia. Drug interactions of concern include estrogen-containing contraceptives (additive thrombotic risk), tissue plasminogen activator and other thrombolytics (antagonized), all-trans retinoic acid in promyelocytic leukemia (fatal thrombosis risk), and factor IX or anti-inhibitor coagulant complex concentrates. Patients on antiplatelet therapy such as clopidogrel or aspirin can usually take tranexamic acid for menstrual bleeding, but the indication for the antiplatelet should be reviewed and the combination kept brief. Postoperative use within seven days of major surgery requires individual discussion. Older patients with declining renal function require periodic dose reassessment to avoid accumulation.

When to Contact Your Doctor

Call 911 or go to the emergency department for sudden chest pain, shortness of breath, calf swelling and pain, vision loss, severe headache, slurred speech, or one-sided weakness - these may signal pulmonary embolism, deep vein thrombosis, or stroke. Persistent visual disturbance or color-vision changes should prompt discontinuation and ophthalmologic evaluation. New seizure activity, particularly in patients with renal impairment or on high doses, requires urgent assessment. Severe headache, severe abdominal pain, hives, swelling, or difficulty breathing warrant emergency care. If menstrual bleeding does not improve after two to three cycles, schedule follow-up to reassess the diagnosis and treatment plan.

If you would like to discuss whether tranexamic acid is the right option for your heavy menstrual bleeding, contact us or schedule a visit with our internal medicine team.